Furazabol

Furazabol (also known as Miotolan) is a derivative of the anabolic steroid dihydrotestosterone (DHT), an androgen that plays a role in male development. Furazabol was first described in 1963 and was used for therapeutic purposes in Japan. Unlike other anabolic steroids, it has a unique structure, with a pyrazole ring attached to the DHT molecule.

Chemical Structure

Furazabol is a 17-alpha-alkylated steroid, which means it has been altered at the 17th carbon position to survive oral ingestion. The addition of a pyrazole ring distinguishes it from other DHT derivatives. This modification is believed to enhance the drug's anabolic properties, making it more effective at promoting muscle growth.

Chemical structure of Furazabol

Medical Uses

Furazabol was used in Japan to treat hypercholesterolemia (high cholesterol levels). It was found to be effective in reducing total cholesterol and triglyceride levels. However, it is no longer used for this purpose due to the availability of safer and more effective medications.

Side Effects

Like other anabolic steroids, Furazabol can have several side effects. These include liver toxicity, negative effects on cholesterol levels, and suppression of natural testosterone production. It may also cause androgenic side effects such as acne, hair loss, and increased aggression.

Legal Status

Furazabol is classified as a controlled substance in many countries, including the United States, where it is listed under Schedule III of the Controlled Substances Act. It is also banned by most sports organizations due to its potential for performance enhancement.

See Also

• Anabolic steroid
• Dihydrotestosterone
• Hypercholesterolemia

References

<references />